Savara (SVRA) Cash & Equivalents (2010 - 2026)
Savara (SVRA) reported Cash & Equivalents of $38.8 million for Q1 2026, up 97.96% year-over-year from $19.6 million in Q1 2025, and up 16.94% on a QoQ basis from $33.2 million in Q4 2025.
Savara (SVRA) has 17 years of Cash & Equivalents data on file, last reported at $38.8 million in Q1 2026.
- Quarterly Cash & Equivalents rose 97.96% year-over-year to $38.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.8 million (up 97.96% YoY) and the FY2025 annual result came in at $33.2 million, up 119.33% from the prior year.
- Cash & Equivalents improved to $38.8 million in Q1 2026 per SVRA's latest filing, from $33.2 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $119.8 million in Q3 2022 and bottomed at $15.1 million in Q4 2024.
- The 5-year median for Cash & Equivalents is $26.6 million (2023), against an average of $38.8 million.
- The widest annual swing landed in 2022, when Cash & Equivalents soared 168.1%; it then plunged 76.89% in 2023.
- Tracing SVRA's Cash & Equivalents over 5 years: stood at $52.1 million in 2022, then tumbled by 48.97% to $26.6 million in 2023, then sank by 43.1% to $15.1 million in 2024, then soared by 119.33% to $33.2 million in 2025, then grew by 16.94% to $38.8 million in 2026.
- Per Business Quant, the three latest SVRA Cash & Equivalents figures stand at $38.8 million (Q1 2026), $33.2 million (Q4 2025), and $16.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 38.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.80 Mn |
| Dec 31, 2025 | 33.18 Mn |
| Sep 30, 2025 | 16.28 Mn |
| Jun 30, 2025 | 17.40 Mn |
| Mar 31, 2025 | 19.60 Mn |
| Dec 31, 2024 | 15.13 Mn |
| Sep 30, 2024 | 21.43 Mn |
| Jun 30, 2024 | 23.90 Mn |
| Mar 31, 2024 | 16.80 Mn |
| Dec 31, 2023 | 26.59 Mn |
| Sep 30, 2023 | 27.69 Mn |
| Jun 30, 2023 | 22.70 Mn |
| Mar 31, 2023 | 33.98 Mn |
| Dec 31, 2022 | 52.10 Mn |
| Sep 30, 2022 | 119.84 Mn |
| Jun 30, 2022 | 95.15 Mn |
| Mar 31, 2022 | 79.20 Mn |
| Dec 31, 2021 | 34.01 Mn |
| Sep 30, 2021 | 44.70 Mn |
| Jun 30, 2021 | 40.70 Mn |
| Mar 31, 2021 | 56.00 Mn |
| Dec 31, 2020 | 22.88 Mn |
| Sep 30, 2020 | 35.20 Mn |
| Jun 30, 2020 | 47.12 Mn |
| Mar 31, 2020 | 34.52 Mn |
| Dec 31, 2019 | 49.80 Mn |
| Sep 30, 2019 | 17.79 Mn |
| Jun 30, 2019 | 16.83 Mn |
| Mar 31, 2019 | 25.67 Mn |
| Dec 31, 2018 | 24.30 Mn |
| Sep 30, 2018 | 24.95 Mn |
| Jun 30, 2018 | 23.60 Mn |
| Mar 31, 2018 | 22.12 Mn |
| Dec 31, 2017 | 22.12 Mn |
| Sep 30, 2017 | 19.81 Mn |
| Jun 30, 2017 | 61.13 Mn |
| Mar 31, 2017 | 10.46 Mn |
| Dec 31, 2016 | 13.37 Mn |
| Sep 30, 2016 | 15.51 Mn |
| Jun 30, 2016 | 14.06 Mn |
| Mar 31, 2016 | 23.52 Mn |
| Dec 31, 2015 | 16.68 Mn |
| Sep 30, 2015 | 32.21 Mn |
| Jun 30, 2015 | 21.21 Mn |
| Mar 31, 2015 | 27.93 Mn |
| Dec 31, 2014 | 12.69 Mn |
| Sep 30, 2014 | 25.98 Mn |
| Jun 30, 2014 | 26.37 Mn |
| Mar 31, 2014 | 29.85 Mn |
| Dec 31, 2013 | 25.68 Mn |
| Sep 30, 2013 | 30.23 Mn |
| Jun 30, 2013 | 44.97 Mn |
| Mar 31, 2013 | 21.41 Mn |
| Dec 31, 2012 | 22.50 Mn |
| Sep 30, 2012 | 26.09 Mn |
| Jun 30, 2012 | 29.96 Mn |
| Mar 31, 2012 | 35.05 Mn |
| Dec 31, 2011 | 43.57 Mn |
| Sep 30, 2011 | 32.77 Mn |
| Jun 30, 2011 | 41.96 Mn |
| Mar 31, 2011 | 46.55 Mn |
| Dec 31, 2010 | 27.98 Mn |
| Sep 30, 2010 | 29.33 Mn |
| Jun 30, 2010 | 31.16 Mn |